Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC designed to combine TOP1i and ATR inhibitor (ATRi) mechanisms for enhanced therapeutic efficacy.

Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis.

Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.

Researchers from Sionna Therapeutics Inc. presented preclinical efficacy data on first-in-class NBD1 stabilizers and their use in combination with complementary modulators to correct cystic fibrosis transmembrane conductance receptor (CFTR) assembly.

Researchers at Astellas Pharma Inc. have reported preclinical efficacy data of ASP-4396, a KRAS G12D degrader.

In atopic dermatitis (AD), the itch-scratch cycle is tied to skin inflammation exacerbation that accelerates the progression of the disease, thus impacting the patient’s quality of life, where IL-31 is crucial to induce skin itching. Helixon Ltd. has developed a bispecific antibody targeting both IL-31 and OX40L, HXN-1022, for the treatment of AD.

ADAM9 (a disintegrin and metalloproteinase 9) is overexpressed in several gastrointestinal cancers, with expression levels correlating with suppressive tumor microenvironment, metastasis and poor prognosis. DB-1317, under development at Duality Biologics (Suzhou) Co. Ltd., is an ADAM9-targeting antibody-drug conjugate including a topoisomerase inhibitor payload P1003 at a drug-antibody ratio of 8.

Alterations in HER2 are known oncogenic drivers in several solid tumors, including breast, lung and gastric cancers, among others. VRN-101099 is an oral and HER2-selective tyrosine kinase inhibitor developed by Voronoi Inc. that had demonstrated brain permeability and preclinical safety.

KIF18A is a kinesin motor protein that moves toward the plus-end of spindle microtubules during mitosis. Inhibition of KIF18A disrupts spindle microtubule dynamics and chromosome alignment, selectively inducing mitotic catastrophe in chromosomally unstable cancer cells while sparing normal cells.